Interview: Aurélien Chaufour – Managing Director, Anjac, France
Aurélien Chaufour reveals how Anjac Health and Beauty has developed with a focus on innovation and industrial know-how since its creation in 2008 and how he today has four companies…
Created in 2008, Anjac Health and Beauty consists of four experts and complementary companies in the areas of health, hygiene, beauty. Anjac is much more than a manufacturer who formulates, manufactures and packages products for companies in the areas of health, beauty and hygiene. Their added value is an ability to imagine and develop innovative customized solutions that make a difference to clients.
Today Anjac has four companies that are expert in the fields of health, hygiene and beauty. First, Shadeline, dynamic company specializing in dermatology and cosmetics. Second, Euro Wipes, a major player in the wipes market, offering a full range of wipes and impregnated cotton pads. Third, Sicaf, a well-established partner of luxury cosmetic brands, known for its expertise in formulation, manufacturing and custom packaging. And lastly, Chemineau, a European specialist in contract development and manufacturing of pharmaceutical products, cosmetics and medical devices. In total they have five manufacturing and R&D facilities. Each year more than a thousand formulations and five thousand products are conceived, manufactured and packaged in their five sites.
Contact
15, rue de la Banque,
75002, PARIS
T : +33 1 53 45 94 49
F : +33 1 53 45 94 59
Aurélien Chaufour reveals how Anjac Health and Beauty has developed with a focus on innovation and industrial know-how since its creation in 2008 and how he today has four companies…
Dominique Pezziardi oversees International Commercial Operations for Stallergenes Greer, a global biotechnology company specialising in allergy therapeutics. With more than 1,200 employees globally – over 600 based in France –…
Erick Lelouche has served as President of Lyonbiopôle since February 2025, bringing more than 35 years of experience in the pharmaceutical industry across Pfizer and Boehringer Ingelheim, spanning human and…
This conversation with Bruno Dubois offers a clear, experience-driven perspective on how Alzheimer’s disease is being redefined, from diagnosis and biomarkers to prevention and early intervention. Drawing on decades at…
Laurence Peyraut serves as Director General of LEEM (Les Entreprises du Médicament), France’s pharmaceutical industry association representing 270 companies ranging from small French generic manufacturers to major multinational innovators. With…
MaaT Pharma is entering a defining moment in its mission to bring microbiotherapies into areas of acute unmet need. Hervé Affagard recounts how a personal catalyst, an engineering mindset and…
Estelle Fruchet, General Manager of Shionogi France since September 2024, brings 25 years of pharmaceutical experience spanning major organisations including Roche, Gilead, and Novartis Gene Therapies. A pharmacist by training…
Genethon sits at the forefront of a fast-accelerating moment in gene medicine, where decades of foundational research are now translating into clinical progress across rare liver, neuromuscular, immune and ophthalmic…
Norgine is redefining what a mid-sized European specialist can achieve, shifting from its gastroenterology heritage into a broader mix of consumer health, women’s health and rare diseases. These changes are…
Frederic Collet, Chairman of FIAC (La Filière Intelligence Artificielle et Cancers), leads a pioneering public-private consortium bringing together nine of the world’s most innovative oncology companies with France’s public health…
Ipsen France is navigating a pivotal moment. The affiliate sits at the intersection of global pipeline expansion, rising expectations for access and renewed national ambition around industrial sovereignty and innovation.…
Jazz Pharmaceuticals’ footprint in France has accelerated over recent years, driven by a sharper focus on rare and complex diseases, a sequence of strategic acquisitions and a growing role in…
Alnylam is reshaping therapeutic possibilities through RNA interference, and France has become one of the strategic environments where this shift is most visible. In this interview, Jean-Baptiste Caquelin reflects on…
See our Cookie Privacy Policy Here
